PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

tute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of

Complete if Known

Application Number 09/837,446

Filing Date April 17, 2001

First Named Inventor BUTCHER, EUGENE C.

Art Unit 1643

Examiner Name MERTZ, PREMA MARIA

Attorney Docket Number STAN-110CON

U.S. PATENT DOCUMENTS								
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
PM		US- 6,488,930 B1	Dec. 3, 2002	Wu et al.				

1

FOREIGN PATENT DOCUMENTS								
Examiner Initials'		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				T ⁶		
		OTHER PRIOR ART—NO	ON PATENT LIT	ERATURE DOCUMENT	S			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), outside and/or country where published.						
PM		HEINEMANN et al., BASOPHIL RESPONSES TO CHEMOKINES ARE REGULATED BY BOTH SEQUENTIAL AND COOPERATIVE RECEPTOR SIGNALING, The Journal of Immunology, 2000, p. 2224-7223						
		IMAI et al., THE T CELL-DIRECTED CC CHEMOKINE TARC IS A HIGHLY SPECIFICA BIOLOGICAL LIGAND FOR CC CHEMOKINE RECEPTOR 4, The Journal of Biological Chemistry, 1997, 272(23): 15036-15042						
		KUNA et al., RANTES, A MCCYTOKINE RELEASES HIS of Immunology, 1997, 149(2):	TAMINE FRO					
		UGUCCIONI et al., HIGH EX CCR3 IN HUMAN BLOOD BA MCP-4, AND OTHER CHEMO	ASOPHILS R	OLE IN ACTIVATIO	N BY EOTAXIN,			

Examiner Signature	Prema	Ment	Date Considered	8/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.